missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human ARC Synthetic Peptide
Description
This peptide corresponds to 14 amino acids near the carboxy terminus of human Nop30. PEP-0399 can be used as a blocking peptide with polyclonal antibody PA5-20305.
ARC (also known as NOL3 - Nucleolar protein 3) has two isoforms. Isoform 1 is involved in RNA splicing. Isoform 2 functions as an apoptosis repressor that blocks multiple modes of cell death. ARC inhibits extrinsic apoptotic pathways two different ways. The first is by interacting with FAS and FADD upon FAS activation blocking death-inducing signaling complex (DISC) assembly. The second way is by interacting with CASP8 in a mitochondria localization-and phosphorylation-dependent manner, which in turn limits the amount of soluble CASP8 avaliable for DISC-mediated activation. ARC also inhibits intrinsic apoptotic pathways in response to a wide range of stresses through interactions with BAX. This results in BAX inactivation and prevents mitochondrial dysfunction and release of pro-apoptotic factors. Mutations affecting the gene can results in myoclonus, familiam cortical.
Specifications
Specifications
| Species | Human |
| Purification Method | purified |
| Accession Number | O60936 |
| Common Name | ARC |
| Concentration | 200 μg/mL |
| Format | Liquid |
| Formulation | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| Gene Alias | activity regulated cytoskeletal-associated protein; activity regulated cytoskeleton associated protein; activity-regulated cytoskeleton-associated protein; Activity-regulated gene 3.1 protein; activity-regulated gene 3.1 protein homolog; Apoptosis repressor with CARD; ARC; arc {ECO:0000312; ARC/ARG3.1; Arc3.1; Arg3.1; B430311C09Rik; C86064; FCM; hArc; KIAA0278; mArc; Muscle-enriched cytoplasmic protein; MYC; MYP; Nol3; NOP; Nop 30; Nop30; Nucleolar protein 3; nucleolar protein 3 (apoptosis repressor with CARD domain); nucleolar protein of 30 kDa; rg3.1; RGD:62037} |
| Gene Symbol | NOL3 |
| Lyophilized | No |
| Show More |